Home›Trial›NCT04923893
🔬NCT04923893Phase 3ACTIVE NOT RECRUITING

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Study Summary

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexamethasone (Rd) maintenance in newly diagnosed multiple myeloma participants for whom ASCT is not planned as initial therapy in terms of Progression Free Survival (PFS).

Conditions
Multiple Myeloma
Interventions / Drugs
BortezomibDexamethasoneLenalidomideCilta-celCyclophosphamideFludarabine
View on ClinicalTrials.gov ↗
Sponsor
JNJ
Johnson & Johnson
Diversified Pharma
C60/100
Study Details
Enrollment743 participants
Primary Completion—
Lead SponsorJanssen Research & Development, LLC
Data Retrieved2026-04-11 02:55:31.550243+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.